‘Viagra for women’ drug to go on sale in September

“There are women who, for no known reason, have reduced sexual desire that causes marked distress”

Hylton V. Joffe

“We are incredibly excited with the FDA’s decision to approve the NDA for Vyleesi as a treatment for premenopausal women with HSDD,” said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. 

“This FDA approval means that premenopausal women with HSDD now have a safe and effective, as-needed treatment option available to them. 

“The Vyleesi approval is an important milestone for Palatin’s employees and shareholders. It reflects our commitment, ability, and dedication to the discovery, development and regulatory approval of novel products with significant unmet medical need and commercial potential.”

The drug, which will go on sale in the US in September, is only the second approved medication to boost sexual desire in women. The first, Addyi, went on sale in 20165 but needs users to take a pill every day. The advantage of Vyleesi is it can be used as needed.

Cynthia Pearson, executive director of the National Women’s Health Network, warned women to avoid using the drug “until more is known about its safety and effectiveness,” pointing out that that the developers had not yet published the results of their clinical trials.

Source: Read Full Article